Inari Medical

What Inari Medical does

Inari Medical is a US-based medical device company that develops mechanical thrombectomy systems for the interventional treatment of venous thromboembolism (VTE) and related vascular conditions. Founded in the 2010s and headquartered in Irvine, California, the company built a purpose-built portfolio including FlowTriever (the first FDA 510(k)-cleared mechanical thrombectomy system for pulmonary embolism), ClotTriever (for deep vein thrombosis, with BOLD and XL variants covering broader vessel sizes including the vena cava), RevCore (the first device for venous in-stent thrombosis), and InThrill (for AV fistula thrombosis), supported by accessories such as the FlowSaver blood return system, Intri24 and Protrieve sheaths, FlowStasis suture device, and VenaCore catheter. The company generated clinical evidence through multiple large registries and studies (CLOUT, FLASH, FLAME, PEERLESS, DEFIANCE) reaching more than 100,000 patients treated.

Inari operated a direct enterprise field-sales model targeting hospitals, healthcare systems, and the interventional cardiologists and vascular surgeons performing thrombectomy procedures, supported by clinical education programs, residents/fellows training, and participation at medical conferences such as VIVA and VEINS. The company also introduced a DVT Per Procedure Pricing (DVT-PPP) model that bundles multiple DVT and peripheral thrombectomy tools under a single per-case price, intended to remove cost as a constraint in physician device selection. In November 2023, Inari expanded beyond VTE by acquiring LimFlow SA for up to $415 million, adding an FDA-approved system for chronic limb-threatening ischemia (CLTI).

In February 2025, Stryker Corporation completed the acquisition of Inari Medical for approximately $4.9 billion ($80 per share), taking the company private and incorporating it as Stryker's entry into the peripheral vascular segment. Prior to the take-private, Inari had been publicly traded on NASDAQ under the ticker NARI and had raised over $200 million in venture funding across Series A through Series E, with Versant Ventures, Andreessen Horowitz, and Redmile Group as key investors. The company operated a European subsidiary (Inari Medical Europe GmbH in Basel, Switzerland) and indicated service across EMEA, APAC, and Latin America/Canada.

Name

Inari Medical

Legal name

Inari Medical, Inc.

Website

https://inarimedical.com

Company type

Private

Founded year

2011

Operating status

Acquired

Headcount range

1,001–5,000 employees

Short description

Inari Medical is a US medical device company that develops mechanical thrombectomy systems (FlowTriever, ClotTriever, RevCore, InThrill) for treating venous thromboembolism, selling directly to hospitals and interventional specialists via enterprise field sales. Acquired by Stryker in February 2025.

Ownership category

akta.pro rank

Product category

Interventional Vascular Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

akta.pro secondary industry

Vascular Access Devices (AV Grafts, Catheters, Fistula Accessories) (HLAHAKAE)

Keywords

• Mechanical thrombectomy systems
• Venous thromboembolism devices
• Interventional vascular devices
• Pulmonary embolism treatment
• Deep vein thrombosis catheters

Headquarters

HQ city

Irvine

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Medical Device Sales: Sale of mechanical thrombectomy systems and associated components (catheters, sheaths) to hospitals and healthcare providers for use in treating VTE conditions.
2. DVT Per Procedure Pricing (DVT-PPP): Provides access to a broad selection of tools for DVT and peripheral thrombectomy at one price per procedure. Enables physicians to make clinical decisions without cost concern and provides locked-in pricing regardless of devices used per case.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Inari Medical designs, manufactures, and sells mechanical thrombectomy systems and procedural accessories used by interventional specialists to treat venous thromboembolism (VTE), including pulmonary embolism, deep vein thrombosis, in-stent thrombosis, and AV fistula thrombosis. Core products include the FDA 510(k)-cleared FlowTriever system for PE, the ClotTriever family (standard, BOLD with HyperClear, and XL) for DVT, the RevCore catheter for in-stent thrombosis, and the InThrill system for AV fistula thrombosis, supported by accessories such as the FlowSaver blood return system, Intri24 and Protrieve sheaths, VenaCore catheter, and FlowStasis device. The LimFlow system for chronic limb-threatening ischemia (CLTI) was added through a 2023 acquisition. Products are sold directly to hospitals and healthcare systems under a per-procedure bundled pricing model.

Product overview

Inari Medical offers a comprehensive portfolio of mechanical thrombectomy systems and accessories designed for the treatment of venous thromboembolism (VTE) and related vascular conditions. The core products include the FlowTriever System (FDA-cleared for pulmonary embolism), ClotTriever System (for deep vein thrombosis), RevCore (for in-stent thrombosis), and InThrill (for AV fistula thrombosis). These purpose-built devices are complemented by supporting accessories including FlowSaver blood return system, Intri24 and Protrieve sheaths, FlowStasis suture retention device, and VenaCore catheter. The ClotTriever family includes specialized variants: standard ClotTriever (vessels 6-16mm), ClotTriever BOLD with HyperClear technology (vessels 10-28mm), and ClotTriever XL for vena cava procedures. In 2023, Inari expanded its portfolio through the acquisition of LimFlow SA and its FDA-approved system for chronic limb-threatening ischemia (CLTI). The company operates on a DVT Per Procedure Pricing (DVT-PPP) model providing all necessary tools at one price per procedure. Products are designed to work without capital equipment, enabling single-session, lytic-free treatments.

Differentiator

Problem solved

Functional benefit

Products and services

• FlowTriever System The FlowTriever System is a mechanical thrombectomy catheter system purpose-built for the treatment of pulmonary embolism (PE). It is the first mechanical thrombectomy device to receive FDA 510(k) clearance for PE and is designed for single-session, lytic-free clot removal, eliminating the need for thrombolytic drugs. It is intended for use by interventional cardiologists and vascular surgeons in hospital catheterization labs and interventional radiology suites.
• ClotTriever System The ClotTriever System is a mechanical thrombectomy device designed for the treatment of deep vein thrombosis (DVT). It uses a nitinol collection bag and atraumatic coring element to capture and remove wall-adherent clot in a single session without thrombolytic drugs. It is intended for use by interventional specialists in hospital settings for DVT patients.
• ClotTriever BOLD Catheter The ClotTriever BOLD Catheter is the next-generation ClotTriever device featuring HyperClear surface treatment technology and a shortened 10 cm collection bag. Designed for vessels 10–28 mm, it delivers wall-to-wall clot removal with faster procedure times and reduced clot adhesion within the collection bag. Intended for interventional specialists treating DVT.
• ClotTriever XL Catheter The ClotTriever XL Catheter is a larger mechanical thrombectomy catheter purpose-built for the vena cava. It features a self-expanding nitinol funnel for 360-degree wall apposition and a 105 cm effective length for extended treatment range. Intended for interventional specialists performing DVT/IVC thrombectomy procedures.
• RevCore Thrombectomy Catheter The RevCore Thrombectomy Catheter is the first mechanical thrombectomy device developed to treat acute to chronic in-stent thrombosis and is the only mechanical thrombectomy device indicated for venous stent thrombosis. It is intended for interventional specialists managing thrombosed venous stents.
• InThrill Thrombectomy System The InThrill Thrombectomy System is an 8 French thrombectomy system purpose-built for the treatment of arteriovenous (AV) fistula thrombosis. It is designed to maximize thrombus removal and restore AV access while operating without capital equipment. Intended for interventional specialists managing dialysis access thrombosis.
• Artix System The Artix System is part of Inari Medical's mechanical thrombectomy innovation portfolio. It is offered to interventional specialists as a thrombectomy procedure solution within the company's broader VTE product line.
• VenaCore Thrombectomy Catheter The VenaCore Thrombectomy Catheter is a mechanical thrombectomy catheter designed for clot removal in the vena cava. It is intended for use by interventional specialists performing IVC thrombectomy procedures.
• FlowSaver Blood Return System The FlowSaver Blood Return System is a procedural accessory that returns aspirated blood to the patient during thrombectomy, enabling bloodless thrombectomy and autologous blood transfusion. Used with Triever catheters, it demonstrated less than 100 mL blood loss in the FLASH registry. Intended for use in hospital interventional suites performing mechanical thrombectomy.
• Intri24 Introducer Sheath The Intri24 Introducer Sheath is a large-bore venous access sheath optimized to facilitate vascular procedures while minimizing blood loss. It serves as the access device for Inari's mechanical thrombectomy catheters in hospital interventional settings.
• Protrieve Sheath The Protrieve Sheath is an introducer sheath designed to provide reliable venous access during complex DVT and IVC thrombectomy cases. It is intended for interventional specialists performing advanced thrombectomy procedures.
• FlowStasis Suture Retention Device The FlowStasis Suture Retention Device is a suture retention device used to support vascular closure during interventional procedures involving Inari's thrombectomy systems.
• ClotTriever Sheath The ClotTriever Sheath is an accessory sheath specifically designed for ClotTriever procedures to support optimal clot removal with minimal blood loss. It features a single-hand operation hemostasis valve to minimize blood loss during insertion and removal of devices.
• LimFlow System The LimFlow System is an FDA-approved medical device system for treating chronic limb-threatening ischemia (CLTI), a severe form of peripheral arterial disease. It was added to Inari Medical's portfolio through the November 2023 acquisition of LimFlow SA for up to $415 million and is sold to vascular specialists and hospitals treating CLTI patients.

Quantifiable outcome

• 99.4% single-session treatment rate (n=499)
• +3 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• Stryker CorporationcoreStrategic or Co-development Partner · 1 February 2025Stryker Corporation completed acquisition of Inari Medical for approximately $4.9 billion in February 2025. The deal provides Stryker entry into the high-growth peripheral vascular segment and expands its offerings in mechanical thrombectomy treatment of blood clots.
• LimFlow SAcoreStrategic or Co-development Partner · 1 November 2023Inari Medical announced acquisition of LimFlow SA in November 2023, valued at up to $415 million ($250 million cash plus milestone payments). LimFlow's FDA-approved system treats chronic limb-threatening ischemia (CLTI). Transaction expected to close in late 2023 to expand Inari's portfolio with innovative vascular disease technologies.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Penumbra: Penumbra's Indigo aspiration system is a directly competing mechanical thrombectomy platform for pulmonary embolism and DVT, sold to the same interventional specialists and hospitals targeted by Inari's FlowTriever and ClotTriever systems.
• AngioDynamics: AngioDynamics' AlphaVac mechanical thrombectomy system is a purpose-built competitor for pulmonary embolism, addressing the same clinical use case as Inari's FlowTriever and targeting the same interventionalist call point.

Broad incumbents

• Boston Scientific: Boston Scientific offers the AngioJet rheolytic thrombectomy system and a broad peripheral vascular portfolio, competing with Inari across PE and DVT while also serving broader interventional cardiology and vascular surgery customers.
• Johnson & Johnson (Cerenovus): Cerenovus, J&J's neurovascular and vascular arm, competes in adjacent stroke and vascular thrombectomy segments and offers broader hospital portfolios that can bundle mechanical thrombectomy against Inari's focused VTE offering.
• Medtronic: Medtronic's peripheral vascular and endovenous portfolios target overlapping interventional specialists and hospital accounts, providing bundled alternatives that can compete against Inari's mechanical thrombectomy systems at the procurement level.
• Abbott: Abbott's vascular division offers peripheral intervention devices used by the same interventional cardiologists and vascular surgeons, making it an indirect but influential competitor for hospital share of vascular procedure budgets.

Others

• Stryker Corporation: Stryker is Inari Medical's parent company following the February 2025 $4.9B acquisition; while not a competitive peer, Stryker's Neurovascular and Peripheral Vascular divisions shape the strategic context, distribution reach, and integration trajectory of the Inari franchise.

Emerging players

• Teleflex: Teleflex (which acquired Vascular Solutions) competes in vascular access and peripheral intervention, with overlapping sheaths and catheters that serve the same interventional call point Inari targets with its Intri24 and Protrieve sheaths.
• Surmodics: Surmodics develops peripheral vascular drug-coated balloons and related devices, representing an emerging alternative therapy that could compete for share-of-mind and procedure budget among the same vascular specialists treating DVT.
• Control Medical Technology: Control Medical Technology develops mechanical thrombectomy aspiration devices, representing an emerging niche competitor with overlapping technology and clinical use cases in VTE treatment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/InariMedical
• Facebookfacebook.com/inarimedical
• LinkedInlinkedin.com/company/inari-medical

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inari Medical